World Tuberculosis Day: Three new medicines recommended by EMA in last six months for patients with multidrug-resistant tuberculosis

April 09, 2104 – Usually, we talk and present here issues on health and disease, therapies notwithstanding which are based on the genetic background (i.e. predisposition) of the individual.  Another aspect of predisposition for dieseas is of course the situation where the genetics of a disease causing agent is at fault. As in the cases of development of resistance of disease causing agents against certain drugs.

Take tuberculosis. Tuberculosis is an infection caused by Mycobacterium tuberculosis that primarily affects the lungs. In 2012, an estimated 8.6 million people developed tuberculosis and 1.3 million died from the disease. Although tuberculosis is slowly declining worldwide, multidrug-resistant tuberculosis still poses a serious public health challenge. It often affects people from the most vulnerable communities, such as migrant workers, refugees, displaced persons, prisoners or drug users. Multidrug-resistant tuberculosis is associated with a substantial mortality rate and poses a significant public-health threat as individuals infected with drug-resistant strains often do not receive adequate treatment and can potentially spread their infection.

Over the past six months, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation to three medicines for the treatment of multidrug-resistant tuberculosis. These include Sirturo (bedaquiline) and Deltyba (delamanid) which are both the first representatives of a new class of medicines against mycobacteria, and Para-aminosalicylic acid Lucane (para-aminosalicylic acid). Situro has been approved in the meantime.

The Agency’s CHMP considered that Sirturo and Deltyba both respond to the high unmet need for new treatment options for pulmonary multidrug-resistant tuberculosis. The data supplied by the applicants demonstrate that the medicines’ benefits outweigh their risks, but are not yet comprehensive; therefore, the CHMP recommended granting conditional approval and the companies must conduct additional studies on the long-term effectiveness of the medicines. Para-aminosalicylic acid Lucane is a new formulation of Para-aminosalicylic acid, which was the second medicine to be introduced for the treatment of tuberculosis in 1946, and was part of standard-of-care treatment until the 1970s. It is recommended in the treatment of multidrug-resistant tuberculosis when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Look here for information on World Tuberculosis Day.

Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • The genetics of side-effects November 25, 2020
    Henk-Jan Guchelaar knows all too well the serious problems that the side-effects of medication can cause. As a professor of clinical pharmacy at the University of Leiden in the Netherlands, he has spent the last two decades trying to get the link between medicine and our genes recognised more widely.
  • Gene donors at high risk for cancer received feedback November 25, 2020
    Researchers at the Estonian Genome Center at the University of Tartu studied how people at high risk for breast, ovarian or prostate cancer responded to the feedback of genetic findings. Gene donors who chose to receive results appreciated being contacted and considered the information provided to be valuable. Authors find that knowing more about people's […]
  • Researchers reveal how genetic variations are linked to COVID-19 disease severity November 25, 2020
    Even as tens of thousands of Americans test positive for COVID-19 each day, physicians still aren't sure why some people experience mild to no symptoms while others become critically ill. New research led by Robert E. Gerszten, MD, Chief of the Division of Cardiovascular Medicine at Beth Israel Deaconess Medical Center (BIDMC) sheds new light […]
  • Study identifies new functions in the gene that causes Machado-Joseph disease November 25, 2020
    Ataxia is a minority disease with genetic origins, known for its neuromuscular alterations due to the selective loss of neurons in the cerebellum, the organ of our nervous systems which controls movement and balance. UB researchers have identified new functions in the ataxin 3 gene (ATXN3)–which causes Machado-Joseph disease, the most common type of ataxia– […]
  • BICRA gene provides answers to patients, doctors and scientists November 23, 2020
    Physicians and scientists are constantly on the lookout for new disease genes that can help them understand why patients have undiagnosed medical problems. Often the first clues come from genetic testing that reveals a change or mutation in a gene that they see in a child but not their parents. This is exactly what led […]
  • Understanding traditional Chinese medicine can help protect species November 26, 2020
    Demystifying traditional Chinese medicine for conservationists could be the key to better protecting endangered species like pangolins, tigers and rhino, according to University of Queensland-led researchers. UQ PhD candidate Hubert Cheung said efforts to shift entrenched values and beliefs about Chinese medicine are not achieving conservation gains in the short term.
  • Satellite images confirm uneven impact of climate change November 26, 2020
    University of Copenhagen researchers have been following vegetation trends across the planet's driest areas using satellite imagery from recent decades. They have identified a troubling trend: Too little vegetation is sprouting up from rainwater in developing nations, whereas things are headed in the opposite direction in wealthier ones. As a result, the future could see […]
  • Survival protein may prevent collateral damage during cancer therapy November 25, 2020
    Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies. The 'cell survival protein', called BCL-XL, was required in laboratory models to keep kidney cells alive and functioning during exposure to chemotherapy or radiotherapy. Kidney damage is a common side effect of these widely used cancer therapies, […]
  • New discovery by SMART allows early detection of shade avoidance syndrome in plants November 25, 2020
    Researchers from Singapore-MIT Alliance for Research and Technology (SMART) have developed a tool that allows early detection of shade avoidance syndrome (SAS) in plants using Raman spectroscopy in significantly less time compared to conventional methods. The discovery can help farmers better monitor plant health and lead to improved crop yield.
  • Psychological factors contributing to language learning November 25, 2020
    Motivation for language learning is a system of cognitive, emotional, and personality-related characteristics.
Top